Table 1.
Patient demographics and baseline characteristics
| Characteristics | N 113 | % |
|---|---|---|
| Age (median, range) | 62 (33–80) | |
| ECOG PS (median, range) | 1 (0–2) | |
| De novo metastatic disease | 10 | (8.8) |
| ER status | ||
| Positive | 87 | (77.0) |
| Negative | 26 | (23.0) |
| PgR status | ||
| Positive | 72 | (63.7) |
| Negative | 38 | (33.6) |
| Unk | 3 | (2.7) |
| Triple negative | 22 | (19.5) |
| HER2 status | ||
| Positive | 11 | (9.7) |
| Negative | 95 | (84.1) |
| Unk | 7 | (6.2) |
| Neo/adjuvant chemotherapy | 82 | (72.5) |
| Adjuvant hormonotherapy | 67 | (59.3) |
| Adjuvant trastuzumab | 4 | (3.5) |
| Number of prior chemotherapy for advanced disease | ||
| 1 | 8 | (7.1) |
| 2 | 26 | (23.0) |
| 3 | 34 | (30.1) |
| 4 | 20 | (17.7) |
| 5 | 14 | (12.4) |
| ≥6 | 11 | (9.7) |
| Median, range | 3 (1–10) | |
| Prior hormonotherapy for advanced disease | 79 | (69.9) |
| Median, range | 2 (1–5) | |
| Number of organs involved | ||
| 1 | 17 | (15.0) |
| 2 | 43 | (38.1) |
| 3 | 33 | (29.2) |
| ≥4 | 20 | (17.7) |
| Median, range | 2 (1–5) | |
| Most common metastatic sites | ||
| Bone | 81 | (71.7) |
| Liver | 60 | (53.1) |
| Lymph nodes | 48 | (42.5) |
| Lung | 36 | (31.8) |
| Skin | 19 | (16.8) |
| CNS | 13 | (11.5) |
| Rechallenge with anthracyclines and/or taxanes | 64 | (56.6) |
ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor 2, CNS central nervous system